Study results indicate that although there are significant differences in HRQOL between the United States and Chile, clinical outcomes were similar.
Administration restrictions on oral mercaptopurine (6-MP) are unnecessary and may impair adherence among children with ALL.
The FDA granted accelerated approval to avelumab for the treatment of patients 12 years and older with Merkel cell carcinoma.
Data suggest that patients whose GIST harbors a KIT exon 11 deletion should receive imatinib for 3 years.
The NCCN is launching is a radiation therapy compendium to guide decision-making for patients receiving radiotherapy.
A study identified gaps in behavioral research, including interventions for targets, use of technology, theory, and environmental manipulation to improve intervention.
Study authors attributed some of the increase in testing among low-risk women to lack of knowledge of health care providers regarding the indication of the test.
Ultrasound findings at mid-NAC were associated with RCB among patients with TNBC and (HR)-negative, HER2-positive disease.
For most patients with breast cancer, the benefits of modern radiotherapy outweigh the risks of future secondary malignancy and heart disease.
Racial disparities in treatment and outcomes persist among patients diagnosed with NSCLC in spite of advances in curative therapies.
SBRT may be an effective strategy for elderly patients with unresectable lung cancer.
Definitive reirradiation of thoracic cancers with IMPT can provide durable local control with minimal toxicity and can extend survival.
ASCO published global recommendations for the primary prevention of cervical cancer in the Journal of Global Oncology.
Post-radiotherapy samples in 20 of 22 recurrences revealed that 15 of these patients (75%) had an increase in CTC counts.
In an analysis of metastatic lung cancer treated with thoracic radiotherapy and immunotherapy, 3 patients had severe toxicity.
Resistance to EGFR-targeted therapies may not be permanent; a single biopsy is insufficient for fully understanding the nature of therapy resistance.
Breast cancer subtype influences the probability that a patient has brain metastases at the time of diagnosis.
Technical standardization and development of the International Scale for reporting Philadelphia chromosome BCR-ABL1 fusion gene expression has improved consistency.
Researchers are evaluating an azacitidine, durvalumab, and tremelimumab combination for the treatment of head and neck cancer.
Researchers are evaluating a home-delivered coping and management strategy system for couples in which one partner has head and neck cancer.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|